Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of Glioblastoma
Jesse A. Coker, Steven R. Martinez, Sang Hoon Han, Anthony R. Sloan, Amit Kumar Gupta, George Bukenya, Paul M. Polzer, James H. Ramos, Emma G. Rico, Annabella Rico, A. Abigail Lindsey, Tanvi Navadgi, Natalie Reitz, Todd Romigh, Jonathan Macdonald, , Shaun R. Stauffer
This study develops triazole-based WDR5 inhibitors that show improved brain penetration and antiproliferative activity against glioblastoma CSCs, with synergistic effects when combined with ATAD2 inhibitors.
JCI Insight · May 5, 2026Peer-reviewedCancer Biology